Results of Operations and Financial Condition. The information provided below in “

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 29, 2026, Traws Pharma, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock was below $1.00 per share for at least 30 consecutive business days, the Company is not currently in compliance with the minimum bi…

Other Events. As previously disclosed in that Current Report on Form 8-K filed by Traws Pharma, Inc. (the “Company”) with the Securities and Exhange Commission (the “Commission”) on March 10, 2025, on March 10, 2025, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with Citizens JMP Securities, LLC (“Citizens”), pursuant to which the Company may offer and sell shares of its common stock, having aggregate sales price of up to $50,000,000 (subject to certain li…

The excerpt is incomplete and does not provide enough information to determine the nature of the event.

Results of Operations and Financial Condition. The information provided below in “

Other Events . On April 15, 2026, the Company issued a press release announcing that the Company had priced the offering of the Purchased Shares and Warrants. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. Forward Looking Statements Some of the statements in this report are forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Securities Exchange Act of…

Results of Operations and Financial Condition. The information provided below in “

in its entirety. Based in part upon the representations of the Investors in the Purchase Agreement, the issuances of the Securities in connection with the Private Placement are exempt from registration under the Securities Act pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder. Each of the Investors represented that they are an “accredited investor” as defined…

Entry into a Material Definitive Agreement PIPE Securities Purchase Agreement On April 15, 2026, Traws Pharma, Inc. (the “Company”) announced the pricing of an offering (the “Private Placement”) of an aggregate of (i) 5,982,919 shares (the “Purchased Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”) (or, in lieu of Purchased Shares, pre-funded warrants to purchase shares of Common Stock (“Pre-Funded Warrants”)), (ii) Series A warrants to initially purchase up…

The filing describes the grant of stock options and restricted stock units to executive officers under a compensation plan.

The excerpt is incomplete and does not provide enough information to determine the nature of the event.

Results of Operations and Financial Condition. The information provided below in “

The filing describes the grant of stock options to executive officers, which is a routine compensatory arrangement.

John Leaman, MD: Dr. John Leaman was appointed as an independent director and member of the Audit Committee.

Completion of Acquisition or Disposition of Assets. The information in

Entry into a Material Definitive Agreement. On September 9, 2025, Traws Pharma, Inc. (the “Company”) and Virom, Inc. (“Viriom”) entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company purchased certain assets (the “Purchased Assets”) from Viriom in exchange for $2,350,000 in cash (the “Purchase Price”), which was paid in full to Virom on September 9, 2025. The Purchased Assets include certain intellectual property and other assets related to a pyrrol…

Results of Operations and Financial Condition. The information provided below in “

Interim Chief Financial Officer — Nora Brennan: Nora Brennan resigned from her role as Interim Chief Financial Officer.

Results of Operations and Financial Condition. The information provided below in “

Interim Chief Executive Officer — Iain Dukes: Dr. Iain Dukes was appointed as the Interim Chief Executive Officer and entered into a new employment agreement.

Results of Operations and Financial Condition. The information provided below in “

Chief Executive Officer — Werner Cautreels: Dr. Werner Cautreels is retiring from his role as CEO, with Iain Dukes appointed as Interim Chief Executive Officer.

Entry into a Material Definitive Agreement. On March 10, 2025, Traws Pharma, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “ATM Agreement”) with Citizens JMP Securities, LLC (“Citizens”), pursuant to which the Company may offer and sell shares of its common stock, having aggregate sales price of up to $50,000,000 (subject to certain limitations set forth in the ATM Agreement), from time to time, to or through Citizens, acting as sales agent and/or principal. Sales…

Entry into a Material Definitive Agreement. As previously disclosed in that Current Report on Form 8-K filed by Traws Pharma, Inc. (the “Company”) with the Securities and Exchange Commission on December 31, 2024, on December 29, 2024, the Company entered into a Securities Purchase Agreement with certain purchasers named therein (the “Purchasers”), pursuant to which, on December 31, 2024, the Company sold and issued to the Purchasers an aggregate of (i) 3,630,205 Class A Units (“Class A Units”…

Chief Financial Officer — Mark Guerin: Mr. Guerin resigned from his position as Chief Financial Officer with a severance package.